Drug Profile

SAGE 689

Alternative Names: SAGE-689

Latest Information Update: 31 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SAGE Therapeutics
Class Antiepileptic drugs; Small molecules; Steroids
Mechanism of Action GABA A receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued CNS disorders; Status epilepticus

Most Recent Events

31 Jan 2025 Discontinued - Phase-I for CNS disorders in USA (IM) before January 2025 (Sage Therapeutics pipeline, January 2025)
31 Jan 2025 Discontinued - Preclinical for Status epilepticus in USA (IM) before January 2025 (Sage Therapeutics pipeline, January 2025)
28 Jun 2024 No recent reports of development identified for phase-I development in CNS-disorders in USA (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com